QTc interval screening in an opioid treatment program

American Journal of Cardiology

Volumn 112, Issue 7, 2013, Pages 1013-1018

  Katz, David F ^a   Sun, Jun ^d   Khatri, Vaishali ^d   Kao, David ^a   Bucher Bartelson, Becki ^d   Traut, Carol ^a,f   Lundin Martinez, John ^f   Goodman, Michael ^f   Mehler, Philip S ^e   Krantz, Mori J ^a,b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CPC Community Health   (United States)

^c Denver Health   (United States)

^d ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

^e NONE   (United States)

^f Health Services and Behavioral Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE;

ARTICLE; DEMOGRAPHY; FOLLOW UP; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; METHADONE TREATMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT INTERVAL; UNITED STATES;

ADULT; ANALGESICS, OPIOID; ARRHYTHMIAS, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MASS SCREENING; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROGRAM EVALUATION; RISK ASSESSMENT;

EID: 84884413108     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.05.037     Document Type: Article

References (26)

1. R.E. Johnson, M.A. Chutuape, E.C. Strain, S.L. Walsh, M.L. Stitzer, and G.E. Bigelow A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence N Engl J Med 343 2000 1290 1297
2. L.J. Paulozzi, K.A. Mack, and C.M. Jones Vital signs: risk for overdose from methadone used for pain relief - United States 1999-2010 Morbid Mortal Wkly Rep 61 2012 493 497
3. R.A. Lugo, K.L. Satterfield, and S.E. Kern Pharmacokinetics of methadone J Pain Palliat Care Pharmacother 19 2005 13 24
4. A.N. Katchman, K.A. McGroary, M.J. Kilborn, C.A. Kornick, P.L. Manfredi, R.L. Woosley, and S.N. Ebert Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents J Pharmacol Exp Ther 303 2002 688 694
5. M.J. Krantz, L. Lewkowiez, H. Hays, M.A. Woodroffe, A.D. Robertson, and P.S. Mehler Torsade de pointes associated with very-high-dose methadone Ann Intern Med 137 2002 501 504
6. D. Kao, B. Bucher-Bartelson, V. Khatri, R. Dart, P.S. Mehler, and M.J. Krantz Trends in reporting of methadone-associated cardiac arrhythmia events, 1997 - 2011 Ann Intern Med 158 2013 735 740
7. M.J. Krantz, J. Martin, B. Stimmel, D. Mehta, and M.C. Haigney QTc interval screening in methadone treatment Ann Intern Med 150 2009 387 395
8. G. Bart CSAT's QT interval screening in methadone report: outrageous fortune or sea of troubles? J Addict Dis 30 2011 313 317
9. R.A. Cruciani Methadone: to ECG or not to ECG.that is still the question J Pain Symptom Manage 36 2008 545 552
10. M.N. Gourevitch First do no harm.reduction? Ann Intern Med 150 2009 417 418
11. M.C. Haigney First, do no harm: QT interval screening in methadone maintenance treatment J Addict Dis 30 2011 309 312
12. B. Stimmel QT or not QT, that is the question: routine electrocardiograms for individuals in methadone maintenance treatment J Addict Dis 30 2011 307 308
13. J.A. Martin, A. Campbell, T. Killip, M. Kotz, M.J. Krantz, M.J. Kreek, B.A. McCarroll, D. Mehta, J.T. Payte, B. Stimmel, T. Taylor, M.C. Haigney, and B.B. Wilford QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel J Addict Dis 30 2011 283 306
14. American Association for the Treatment of Opioid Dependence. QTc Interval Screening - AATOD Policy and Guidance Statement. Available at: http://www.aatod.org/qtc.html. Accessed May 10, 2012.
15. P.A. Harris, R. Taylor, R. Thielke, J. Payne, N. Gonzalez, and J.G. Conde Research Electronic Data Capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support J Biomed Inform 42 2009 377 381
16. E. Peles, G. Bodner, M.J. Kreek, V. Rados, and M. Adelson Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study Addiction 102 2007 289 300
17. E.F. Wedam, G.E. Bigelow, R.E. Johnson, P.A. Nuzzo, and M.C. Haigney QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial Arch Intern Med 167 2007 2469 2475
18. B.A. Martell, J.H. Arnsten, M.J. Krantz, and M.N. Gourevitch Impact of methadone treatment on cardiac repolarization and conduction in opioid users Am J Cardiol 95 2005 915 918
19. M.M. Bednar, E.P. Harrigan, and J.N. Ruskin Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc Am J Cardiol 89 2002 1316 1319
20. A. Fareed, S. Vayalapalli, J. Byrd-Sellers, J. Casarella, K. Drexler, R. Amar, J. Smith-Cox, and T.S. Lutchman Onsite QTc interval screening for patients in methadone maintenance treatment J Addict Dis 29 2010 15 22
21. S. Mayet, M. Gossop, N. Lintzeris, V. Markides, and J. Strang Methadone maintenance, QTc and Torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation? Drug Alcohol Rev 30 2011 388 396
22. C. Barbhaiya, R.M. Seewald, and S. Hanon QT prolongation and arrhythmia risk in methadone maintenance treatment J Innov Card Rhythm Managet 2 2011 566 568
23. M.J. Krantz, I.B. Kutinsky, A.D. Robertson, and P.S. Mehler Dose-related effects of methadone on QT prolongation in a series of patients with Torsade de pointes Pharmacotherapy 23 2003 802 805
24. D. Zeltser, D. Justo, A. Halkin, V. Prokhorov, K. Heller, and S. Viskin Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors Medicine (Baltimore) 82 2003 282 290
25. US Food and Drug Administration, Center for Drug Evaluation and Research Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs 2005 US Food Drug and Administration, Center for Drug Evaluation and Research Rockville, Maryland
26. J. Florian, C.E. Garnett, S.C. Nallani, B.A. Rappaport, and D.C. Throckmorton A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients Clin Pharmacol Ther 91 2012 666 672